Status:
COMPLETED
Vyndaqel Capsules Special Investigation (ATTR-CM)
Lead Sponsor:
Pfizer
Conditions:
Transthyretin (TTR) Amyloid Cardiomyopathy
Eligibility:
All Genders
Brief Summary
Secondary Data Collection : To confirm the safety and effectiveness profiles under the actual medical practice of Vyndaqel in Japan. This study is conducted in accordance with the protocol even when V...
Detailed Description
To comprehend information on the long-term safety (e.g., onset status of adverse reactions), etc. of patients who are treated with Vyndaqel for the treatment of transthyretin amyloid cardiomyopathy. W...
Eligibility Criteria
Inclusion
- Patients administered Vyndaqel for the treatment of ATTR-CM
Exclusion
- N/A
Key Trial Info
Start Date :
October 3 2019
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
March 27 2025
Estimated Enrollment :
1214 Patients enrolled
Trial Details
Trial ID
NCT04108091
Start Date
October 3 2019
End Date
March 27 2025
Last Update
May 8 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Pfizer
Tokyo, Japan